Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter D Senter

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
Nature Biotechnology|June 5, 2003
Development of potent monoclonal antibody auristatin conjugates for cancer therapySvetlana O Doronina, Brian E Toki, Michael Y Torgov, et al.
Blood|April 26, 2003
cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activityJoseph A Francisco, Charles G Cerveny, Damon L Meyer, et al.
Molecular Cancer Therapeutics|March 6, 2016
Development of Novel Quaternary Ammonium Linkers for Antibody-Drug ConjugatesPatrick J Burke, Joseph Z Hamilton, Thomas A Pires, et al.
Bioconjugate Chemistry|May 24, 2024
Reversible Chemical Modification of Antibody Effector Function Mitigates Unwanted Systemic Immune ActivationPhilip N Moquist, Xinqun Zhang, Chris I Leiske, et al.
Molecular Cancer Therapeutics|October 29, 2025
Targeted delivery of a potent STING agonist payload via an antibody drug conjugate drives robust antitumor activity in preclinical modelsDavid R Gruber, Elizabeth J Cummins, Weiping Zeng, et al.
Molecular Cancer Therapeutics|September 23, 2018
Targeted Delivery of Cytotoxic NAMPT Inhibitors Using Antibody-Drug ConjugatesChristopher S Neumann, Kathleen C Olivas, Martha E Anderson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2006
CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanomaKam Fai Tse, Michael Jeffers, Vincent A Pollack, et al.
Blood|June 18, 2013
SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AMLMay S Kung Sutherland, Roland B Walter, Scott C Jeffrey, et al.
Molecular Cancer Therapeutics|December 4, 2020
Development of Novel Antibody-Camptothecin ConjugatesRyan D Lyski, Lauren B Bou, Uland Y Lau, et al.
Cancer Research|February 21, 2006
Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugatesChe-Leung Law, Kristine A Gordon, Brian E Toki, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
Nature Biotechnology|June 5, 2003
Development of potent monoclonal antibody auristatin conjugates for cancer therapySvetlana O Doronina, Brian E Toki, Michael Y Torgov, et al.
Blood|April 26, 2003
cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activityJoseph A Francisco, Charles G Cerveny, Damon L Meyer, et al.
Molecular Cancer Therapeutics|March 6, 2016
Development of Novel Quaternary Ammonium Linkers for Antibody-Drug ConjugatesPatrick J Burke, Joseph Z Hamilton, Thomas A Pires, et al.
Bioconjugate Chemistry|May 24, 2024
Reversible Chemical Modification of Antibody Effector Function Mitigates Unwanted Systemic Immune ActivationPhilip N Moquist, Xinqun Zhang, Chris I Leiske, et al.
Molecular Cancer Therapeutics|October 29, 2025
Targeted delivery of a potent STING agonist payload via an antibody drug conjugate drives robust antitumor activity in preclinical modelsDavid R Gruber, Elizabeth J Cummins, Weiping Zeng, et al.
Molecular Cancer Therapeutics|September 23, 2018
Targeted Delivery of Cytotoxic NAMPT Inhibitors Using Antibody-Drug ConjugatesChristopher S Neumann, Kathleen C Olivas, Martha E Anderson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2006
CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanomaKam Fai Tse, Michael Jeffers, Vincent A Pollack, et al.
Blood|June 18, 2013
SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AMLMay S Kung Sutherland, Roland B Walter, Scott C Jeffrey, et al.
Molecular Cancer Therapeutics|December 4, 2020
Development of Novel Antibody-Camptothecin ConjugatesRyan D Lyski, Lauren B Bou, Uland Y Lau, et al.
Cancer Research|February 21, 2006
Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugatesChe-Leung Law, Kristine A Gordon, Brian E Toki, et al.
Pageof 9